Eurofins Has Signed an Exclusive Agreement to Acquire Amatsigroup to Further Expand Its Leadership in Biopharmaceutical Servi...
2017年7月10日 - 3:00PM
ビジネスワイヤ(英語)
Regulatory News:
Eurofins Scientific (EUFI.PA) (Paris:ERF), a global leader in
bio-pharmaceutical products testing, and one of the world leaders
in genomic services, announces that it has signed an exclusive
agreement with Ekkio Capital to acquire the Amatsigroup for a price
of approximately EUR 130m plus some residual debt at closing. The
contemplated transaction is expected to be completed over the next
few months, subject to customary closing conditions including
employees' representatives' information and consultation.
Amatsigroup is a leading international contract development and
manufacturing organization (CDMO) providing preclinical and
clinical phase services for the development of human and veterinary
drugs. Founded in 2010 by Ekkio Capital, it was formed through the
merger of four French companies (Avogadro, Amatsi, DBI and
Avepharm) bringing complementary expertise and a cumulative
experience in the field of over 30 years. As of 2014, Amatsigroup
began to expand internationally with the acquisition of its
subsidiaries SEPS Pharma in Belgium and Amatsigroup Inc. (Indiana,
USA). Its expansion continued in 2015 with the acquisition of
Pierre Fabre's pharmaceutical analysis laboratory in
Saint-Augustin, France. In 2016, the group expanded its activity
through the acquisition of QBiologicals, a Belgian company
specialized in bioprocess development & biomanufacturing. In
early 2017, Amatsigroup strengthened its sterile capacities with
the acquisition of Disposable Lab and even more recently signed an
exclusive agreement to acquire two sites in France from Bertin
Pharma with a strong expertise in galenic formulation and
development. This acquisition is expected to be closed during the
summer.
Amatsigroup is one of the largest independent multi-specialist
platforms in Europe with a unique proposal for specialty and
biopharma clients, including biopharmaceutical analysis,
formulation development and manufacturing, biological research
& development, among other services. The company employs about
450 staff and plans to generate over EUR 60m revenues in 2017 on a
pro forma basis, with an EBITDA margin already above Eurofins
overall group target.
Amatsigroup has 8 sites in France (including the sites acquired
from Bertin Pharma), 2 sites in Belgium and 1 site in the USA. The
company is organized in five business units and delivers a
differentiated specialist offer focused on biotechnology companies
and mid-size pharma companies, supported by strong technical
capabilities and project management over the whole development
cycle. Given its unique positioning as a high value added
multi-specialist drug development services provider, the company is
well-positioned to leverage and strengthen its footprint in the
CDMO industry.
Should the contemplated transaction come to closing, the
addition of Amatsigroup to the Eurofins network would strengthen
the Group's biopharma product testing biopharmaceutical service
offering, and strengthen its growing presence in the field of
formulation, development and manufacturing of new drugs, following
the acquisition of Alphora in Canada earlier this year.
Comment from Alain Sainsot, Managing Director of
Amatsigroup: “Over the past 6 years, thanks to the support of our
shareholder Ekkio Capital, the company has become a leader in its
sector. The Eurofins network would now offer us the opportunity to
develop our multi-specialist platform proposal in other countries,
get access to Eurofins group international clients as well as to
Eurofins globally standardized IT and quality management solutions
and generally to strengthen our position as a leader in the CDMO
sector in France and other parts of Europe.”
Comment from Dr. Gilles Martin, Eurofins CEO: “The
acquisition of the Amatsi Group is reinforcing Eurofins leadership
position into the BioPharma services line of business. Amatsi’s
fast growing contract development and manufacturing (CDM) services
is enabling Eurofins entry this attractive space in Europe and will
be very complementary to our growing network of biopharma product
testing activities in Europe. Together with Alphora, recently
acquired in Canada, Eurofins is now ready to service its customers
on two continents in the CDMO space.”
For more information, please visit
www.eurofins.com.
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter
sometimes “Eurofins” or “the Group”) believes it is the world
leader in food, environment and pharmaceutical products testing and
that it is also one of the global independent market leaders in
certain testing and laboratory services for agroscience, genomics,
discovery pharmacology and for supporting clinical studies. In
addition, Eurofins is one of the key emerging players in specialty
clinical diagnostic testing in Europe and the USA. With over 28,000
staff in 310 laboratories across 39 countries, Eurofins offers a
portfolio of over 130,000 analytical methods for evaluating the
safety, identity, composition, authenticity, origin and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group objective is to provide its
customers with high-quality services, accurate results on time and
expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’s management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170709005077/en/
Investor RelationsEurofins ScientificPhone: +32 2 766
1620E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
過去 株価チャート
から 6 2024 まで 7 2024
Enerplus (NYSE:ERF)
過去 株価チャート
から 7 2023 まで 7 2024